IP Library Granted Patent US 9,757,336
Granted Patent B2
US 9,757,336 · App. 13/786,945 · Granted Sep 12, 2017

Method for formulating large diameter synthetic membrane vesicles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,757,336
App. No.
13/786,945
Granted
Sep 12, 2017
Kind
B2
Abstract

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Claims (43)

1. A process for making multivesicular liposomes using an atomizing nozzle apparatus, wherein the apparatus comprises:

a first fluid conduit and a second fluid conduit each having at least one entrance orifice and at least one exit orifice;

a fluid contacting chamber having a top comprising at least one entrance orifice and having a bottom comprising at least one exit orifice and connecting to the at least one exit orifice of the first fluid conduit, wherein the fluid contacting chamber conically narrows in diameter from the top of the fluid contacting chamber to the exit orifice of the fluid contacting chamber; and

a third fluid conduit, wherein the third fluid conduit annularly surrounds a portion of the fluid contacting chamber,

wherein the process for making multivesicular liposomes comprises:

applying a first liquid to the first fluid conduit, wherein the first liquid comprises an organic solvent;

applying a second liquid to the second fluid conduit;

applying a pressurized gas to the third fluid conduit to provide atomized droplets, wherein the pressurized gas exiting the third fluid conduit exit orifice impinges the liquid exiting the fluid contacting chamber exit orifice; and

removing the organic solvent from the atomized droplets, wherein less than 4000 ppm of the organic solvent remains in the atomized droplets, resulting in formation of multivesicular liposomes.

2. The process of claim 1 , wherein the first liquid is an emulsion comprised of:

a discontinuous aqueous phase; and

a continuous organic phase comprising the organic solvent.

3. The process of claim 2 , wherein the organic solvent is methylene chloride or chloroform.

4. The process of claim 2 , wherein the discontinuous aqueous phase further comprises a therapeutic agent.

5. The process of claim 2 , wherein the continuous organic phase further comprises a therapeutic agent.

6. The process of claim 5 , wherein the therapeutic agent is bupivacaine or a salt thereof.

7. The process of claim 1 , wherein the second liquid applied to the second fluid conduit is an aqueous solution.

8. The process of claim 7 , wherein the aqueous solution further comprises either dextrose or lysine, or a mixture thereof.

9. The process of claim 1 , wherein the gas is a sterilized gas.

10. The process of claim 9 , wherein the sterilized gas is nitrogen.

11. The process of claim 1 , wherein the atomized droplets contain organic solvent in the range of from about 400 ppm to about 3500 ppm after solvent removal.

12. The process of claim 4 , wherein the therapeutic agent is bupivacaine or a salt thereof.

13. A process for making multivesicular liposomes using an evaporation apparatus comprising,

wherein the evaporation apparatus comprises:

a solvent removal vessel having a top, a bottom, and a circular wall,

at least one atomizing nozzle,

at least one carrier gas entrance orifice,

a solvent removal gas exit orifice centrally connected to the top, and

a product exit orifice connected to the bottom of the vessel;

wherein the at least one atomizing nozzle comprises:

a first fluid conduit a second fluid conduit each having at least one entrance orifice and at least one exit orifice;

a fluid contacting chamber having a top comprising at least one entrance orifice and having a bottom comprising at least one exit orifice and connecting to the at least one exit orifice of the first fluid conduit, wherein the fluid contacting chamber conically narrows in diameter from the top of the fluid contacting chamber to the exit orifice of the fluid contacting chamber; and

a third fluid conduit, wherein the third fluid conduit annularly surrounds a portion of the fluid contacting chamber,

wherein the process for making multivesicular liposomes comprises:

applying a first liquid to the first fluid conduit, wherein the first liquid comprises an organic solvent;

applying a second liquid to the second fluid conduit;

applying a pressurized gas to the third fluid conduit to provide atomized droplets, wherein the pressurized gas exiting the third fluid conduit exit orifice impinges the liquid exiting the fluid contacting chamber exit orifice; and

removing the organic solvent from the atomized droplets wherein the step of removing the organic solvent from the atomized droplets comprises:

introducing atomized droplets from the at least one atomizing nozzle into the evaporation apparatus,

introducing a pressurized carrier gas tangentially to the circular wall into the solvent removal vessel through one of the at least one carrier gas entrance orifices; and

removing a solvent removal gas wherein the solvent removal gas removes greater than 90% of the organic solvent in the atomized droplets resulting in formation of multivesicular liposomes.

14. The process of claim 13 , wherein the carrier gas is heated and humidified.

15. The process of claim 13 , further comprising spraying a wall rinse solution into the solvent removal vessel using a rinse nozzle, wherein the wall rinse solution prevents build-up of particles in the evaporation apparatus.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
SECURITY INTEREST Recorded Jul 4, 2025
From: PACIRA PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071814/0792 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 31, 2023
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 063213/0864 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Dec 14, 2021
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; FLEXION THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058516/0636 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: SCHUTT, ERNEST GEORGE; MCGUIRE, RONALD WARREN; WALTERS, PETER ANDREW; LOS, KATHLEEN D.A.
To: PACIRA PHARMACEUTICALS, INC.
Reel/Frame 037077/0554 →